Business Description
ARS Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US82835W1080
Description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1367.15 | |||||
| Equity-to-Asset | 0.97 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 122.25 | |||||
| Beneish M-Score | -2.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -421.5 | |||||
| 3-Year EPS without NRI Growth Rate | -272.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 1616.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.57 | |||||
| 9-Day RSI | 55.52 | |||||
| 14-Day RSI | 56.89 | |||||
| 6-1 Month Momentum % | 25.18 | |||||
| 12-1 Month Momentum % | 198.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 32.82 | |||||
| Quick Ratio | 32.82 | |||||
| Cash Ratio | 32.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | 0.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -11347.2 | |||||
| Net Margin % | -8968.4 | |||||
| FCF Margin % | -8846 | |||||
| ROE % | -19.4 | |||||
| ROA % | -18.84 | |||||
| ROIC % | -1365.03 | |||||
| 3-Year ROIIC % | 2154.6 | |||||
| ROC (Joel Greenblatt) % | -6039.6 | |||||
| ROCE % | -24.54 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2838 | |||||
| PB Ratio | 6.39 | |||||
| Price-to-Tangible-Book | 6.39 | |||||
| EV-to-EBIT | -20.39 | |||||
| EV-to-EBITDA | -21.77 | |||||
| EV-to-Revenue | 2314.03 | |||||
| EV-to-FCF | -26.16 | |||||
| Price-to-Net-Current-Asset-Value | 6.42 | |||||
| Price-to-Net-Cash | 6.48 | |||||
| Earnings Yield (Greenblatt) % | -4.9 | |||||
| FCF Yield % | -3.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SPRY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ARS Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.5 | ||
| EPS (TTM) ($) | -0.47 | ||
| Beta | 0 | ||
| Volatility % | 55.76 | ||
| 14-Day RSI | 56.89 | ||
| 14-Day ATR ($) | 0.847761 | ||
| 20-Day SMA ($) | 13.653 | ||
| 12-1 Month Momentum % | 198.25 | ||
| 52-Week Range ($) | 3.35 - 16.5 | ||
| Shares Outstanding (Mil) | 96.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ARS Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ARS Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ARS Pharmaceuticals Inc Frequently Asked Questions
What is ARS Pharmaceuticals Inc(SPRY)'s stock price today?
The current price of SPRY is $14.19. The 52 week high of SPRY is $16.50 and 52 week low is $3.35.
When is next earnings date of ARS Pharmaceuticals Inc(SPRY)?
The next earnings date of ARS Pharmaceuticals Inc(SPRY) is 2024-11-08 Est..
Does ARS Pharmaceuticals Inc(SPRY) pay dividends? If so, how much?
ARS Pharmaceuticals Inc(SPRY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers